News
ESMO26: Sac-TMT delivers the goods in PD-L1-negative NSCLC
Kelun and MSD's TROP2-directed ADC, sac-TMT, reduced the risk of disease progression or death by 51% when used first-line in PD-L1-negative NSCLC.
News
ESMO26: Bayer's Nubeqa finds new prostate cancer role
Bayer's prostate cancer drug Nubeqa has reduced the risk of the disease spreading or death by 58% in patients at high risk of disease recurrence.
News
ESMO26: 'Unprecedented' results from DeLLphi-305 in SCLC
Amgen has revealed data that it hopes will move its DLL3-targeting T cell engager Imdelltra into the first-line setting in small cell lung cancer.
News
ESMO26: VOLGA stirs up perioperative bladder cancer therapy
The VOLGA trial shows that Imfinzi and Padcev could be a rival Keytruda+Padcev in perioperative treatment of muscle-invasive bladder cancer.
News
ESMO26: Lilly's sofe-m ADC stakes a claim in ovarian cancer
Eli Lilly's first major readout at ESMO comes from a phase 1 trial of its FRα-targeting sofe-m in platinum-sensitive ovarian cancer (PSOC).
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
